A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV

NCT03213405 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: rBCG-N-hRSV 1/100
BIOLOGICAL: rBCG-N-hRSV 1/10
BIOLOGICAL: rBCG-N-hRSV full dose
BIOLOGICAL: Conventional BCG full dose

Sponsor

Pontificia Universidad Catolica de Chile

Collaborators

[object Object]
[object Object]